Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) - USD ($)						12 Months Ended
	Feb. 16, 2021	Nov. 30, 2020	Nov. 24, 2020	Mar. 27, 2020	Feb. 12, 2020	Dec. 31, 2021	Dec. 31, 2020	Nov. 25, 2020
Controlled equity offering sales agreement
Common stock, par value (in dollars per share)						$ 0.0001	$ 0.0001
Proceeds from public offering, net of underwriting discounts, commissions and offering expenses						$ 82,153,600	$ 42,866,272
February 16, 2021 Warrants | Warrants
Controlled equity offering sales agreement
Warrants issued (in shares)	1,105,000
Exercise price per share (in dollars per share)	$ 2.50
Exercise commencement period for warrants	180 days
November 24, 2020 Warrants | Warrants
Controlled equity offering sales agreement
Warrants issued (in shares)			690,000
Exercise price per share (in dollars per share)								$ 1.875
Exercise commencement period for warrants		180 days
Sales Agreement
Controlled equity offering sales agreement
Issuance of common stock, net (in shares)	44,200,000			2,950,939	2,311,867		5,262,806
Offering price (in dollars per share)	$ 2.00
Proceeds from public offering, net of underwriting discounts, commissions and offering expenses	$ 82,100,000			$ 4,600,000			$ 11,200,000
Maximum aggregate offering price					$ 6,800,000
Underwriters
Controlled equity offering sales agreement
Issuance of common stock, net (in shares)			20,000,000
Offering price (in dollars per share)			$ 1.50
Proceeds from public offering, net of underwriting discounts, commissions and offering expenses			$ 31,600,000
Term of option to purchase			45 days
Exercise period for warrants		4 years 6 months
Underwriters | Maximum
Controlled equity offering sales agreement
Issuance of common stock, net (in shares)			3,000,000